PACS Rebound Validates Thesis, But Discount Narrows

What happened

PACS Group shares have surged 257% from oversold lows, reflecting strong execution and improving fundamentals. The company maintains robust credit with $795M liquidity and 0.1x net leverage, supporting continued acquisition-driven growth. FY26 guidance projects 8% revenue growth and 22% adjusted EBITDA growth, driven by facility maturation and margin expansion. The DeepValue thesis highlighting the repeatable integration model and demographic tailwinds has been largely validated. However, the valuation discount has compressed significantly, reducing the margin of safety versus the initial BUY case.

Implication

The 257% rally has compressed the valuation to more normalized levels, reducing the initial deep value margin of safety. Investors should now focus on execution against FY26 guidance and margin expansion. Key risks remain labor costs and reimbursement timing, which could create volatility. Continued improvement in occupancy and skilled mix in newer facilities is critical to sustain the multiple. For existing holders, the thesis remains intact but with less upside; new entries require patience at current prices.

Thesis delta

The core thesis of a repeatable integration playbook and demographic tailwinds is confirmed. However, the deep value discount has largely closed, shifting the risk/reward from compelling to more balanced. The focus now is on execution to deliver the guided growth and margin expansion.